Search

Your search keyword '"William Greenhalf"' showing total 257 results

Search Constraints

Start Over You searched for: Author "William Greenhalf" Remove constraint Author: "William Greenhalf" Language undetermined Remove constraint Language: undetermined
257 results on '"William Greenhalf"'

Search Results

1. Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation

2. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma

3. Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)

4. Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways

7. Supplementary Tables 1-5 from Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors

11. Supplementary Figure 3 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

12. Supplementary Figure S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

13. Supplementary Figure S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

14. Supplementary figures 1-4 from Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

15. Supplementary Figure S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

16. Supplementary Table S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

17. Supplementary Table 3 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties

18. Supplementary Figure 6 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

19. Supplementary Table S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

20. Supplementary Table 4 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties

21. Supplementary Figure 4 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

22. Data from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties

23. Supplementary Figure Legends from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

24. Supplementary Table S4. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

25. Supplementary Figure 5 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

26. Supplementary Table S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

27. Supplementary Table 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties

28. Supplementary Table 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties

29. Supplementary Figure 2 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

30. Data from Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

31. Supplementary Table S5. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

32. Supplementary Table 1 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

33. Supplemental Methods from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties

34. Supplementary Figure 1 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

36. SUPPLEMENTARY DATA from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

37. Data from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus

38. Supplementary Materials and Methods, Supplementary Figures 1 through 9, and Supplementary Tables 1 through 4 from Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression

39. Data from Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression

40. Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset

41. Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: An international expert survey and case vignette study

42. Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning

43. United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer

44. A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2

45. Author response for 'Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients'

46. The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer

47. Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties

48. Early detection of pancreatic ductal adenocarcinomas with an ensemble learning model based on a panel of protein serum biomarkers

49. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

50. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study

Catalog

Books, media, physical & digital resources